{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:36:24Z","timestamp":1787236584544,"version":"build-2736575974"},"reference-count":50,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,8]]},"DOI":"10.31744\/einstein_journal\/2026rw1656","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:30:33Z","timestamp":1775827833000},"source":"Crossref","is-referenced-by-count":1,"title":["Irreversible electroporation combined with immunotherapy versus irreversible electroporation alone for locally advanced pancreatic cancer: a systematic review and meta-analysis"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-8900","authenticated-orcid":false,"given":"Miriana","family":"Mariussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1035-2902","authenticated-orcid":false,"given":"Laura Costa de Oliveira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-4581","authenticated-orcid":false,"given":"Mariano Gallo","family":"Ruelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8742-1818","authenticated-orcid":false,"given":"Victor Arthur","family":"Ohannesian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0391-0872","authenticated-orcid":false,"given":"Bruno","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8702-5541","authenticated-orcid":false,"given":"Guilherme Strieder de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-6379","authenticated-orcid":false,"given":"Luiza Giuliani","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-1370","authenticated-orcid":false,"given":"Giovanni Brondani","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-1916","authenticated-orcid":false,"given":"Stephan","family":"Altmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-9174","authenticated-orcid":false,"given":"Priscila Mina","family":"Falsarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1374","authenticated-orcid":false,"suffix":"Junior","given":"Pedro Luiz Serrano","family":"Us\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-9595","authenticated-orcid":false,"given":"Rodrigo Gobbo","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"32","key":"key20260410133028_B1","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","unstructured":"1 Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022;28(32):4698-715.","journal-title":"World J Gastroenterol"},{"issue":"36","key":"key20260410133028_B2","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.2217\/fon-2021-0533","article-title":"Surgery for pancreatic cancer: current controversies and challenges","volume":"17","author":"Karunakaran","year":"2021","unstructured":"2 Karunakaran M, Barreto SG. Surgery for pancreatic cancer: current controversies and challenges. Future Oncol. 2021;17(36):5135-62.","journal-title":"Future Oncol"},{"issue":"1","key":"key20260410133028_B3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.currproblcancer.2017.10.006","article-title":"Locally advanced pancreatic cancer: an emerging entity","volume":"42","author":"O Kane","year":"2018","unstructured":"3 O Kane GM, Knox JJ. Locally advanced pancreatic cancer: an emerging entity. Curr Probl Cancer. 2018;42(1):12-25.","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"key20260410133028_B4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","unstructured":"4 Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439-57.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"key20260410133028_B5","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The Role of Immunotherapy in Pancreatic Cancer","volume":"29","author":"Mukherji","year":"2022","unstructured":"5 Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022;29(10):6864-92.","journal-title":"Curr Oncol"},{"issue":"10","key":"key20260410133028_B6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"O'Reilly","year":"2019","unstructured":"6 O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(10):1431-8.","journal-title":"JAMA Oncol"},{"issue":"27","key":"key20260410133028_B7","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","unstructured":"7 Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, et al. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). J Clin Oncol. 2022;40(27):3180-9.","journal-title":"J Clin Oncol"},{"issue":"3","key":"key20260410133028_B8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.23736\/S0026-4733.18.07881-1","article-title":"Ablation treatments in unresectable pancreatic cancer","volume":"74","author":"Paiella","year":"2019","unstructured":"8 Paiella S, De Pastena M, Romeo F, D'onofrio M, Fontana M, Pea A, et al. Ablation treatments in unresectable pancreatic cancer. Minerva Chir. 2019;74(3):263-9.","journal-title":"Minerva Chir"},{"issue":"2","key":"key20260410133028_B9","doi-asserted-by":"crossref","first-page":"100675","DOI":"10.1016\/j.tvir.2020.100675","article-title":"Irreversible Electroporation for Locally Advanced Pancreatic Cancer","volume":"23","author":"Timmer","year":"2020","unstructured":"9 Timmer FE, Geboers B, Ruarus AH, Schouten EA, Nieuwenhuizen S, Puijk RS, et al. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Tech Vasc Interv Radiol. 2020;23(2):100675.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"12","key":"key20260410133028_B10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.jvir.2018.07.009","article-title":"Early Immunologic Response of Irreversible Electroporation versus Cryoablation in a Rodent Model of Pancreatic Cancer","volume":"29","author":"White","year":"2018","unstructured":"10 White SB, Zhang Z, Chen J, Gogineni VR, Larson AC. Early Immunologic Response of Irreversible Electroporation versus Cryoablation in a Rodent Model of Pancreatic Cancer. J Vasc Interv Radiol. 2018;29(12):1764-9.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"key20260410133028_B11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1148\/radiol.2015151166","article-title":"Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model","volume":"280","author":"Bulvik","year":"2016","unstructured":"11 Bulvik BE, Rozenblum N, Gourevich S, Ahmed M, Andriyanov AV, Galun E, et al. Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model. Radiology. 2016;280(2):413-24.","journal-title":"Radiology"},{"key":"key20260410133028_B12","volume-title":"Zotero (Version 7.0.3)","year":"2024","unstructured":"12 Zotero (Version 7.0.3). EUA; 2024 [cited 2024 Oct 8]. Available: https:\/\/www.zotero.org\/"},{"key":"key20260410133028_B13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","unstructured":"13 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"key20260410133028_B14","author":"Bossuyt","unstructured":"14 Bossuyt PM, Deeks JJ, Leeflang MM, Takwoingi Y, Flemyng E. Preface, \"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023).\" The Cochrane Collaboration: [cited 2024 oct 8]. Available from: https:\/\/training.cochrane.org\/handbook-diagnostic-test-accuracy\/current","journal-title":"Preface, \"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023).\""},{"key":"key20260410133028_B15","author":"Rohatgi","unstructured":"15 Rohatgi A. WebPlotDigitizer (Version 4.7) [Software]. [cited 2024 Oct 8]. Available: https:\/\/automeris.io\/v4\/","journal-title":"WebPlotDigitizer (Version 4.7) [Software]"},{"key":"key20260410133028_B16","author":"R Core Team","unstructured":"16 R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. [cited 2024 jun 13] Available: https:\/\/www.R-project.org\/","journal-title":"A Language and Environment for Statistical Computing"},{"issue":"60","key":"key20260410133028_B17","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.18632\/oncotarget.21974","article-title":"An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer","volume":"8","author":"Lin","year":"2017","unstructured":"17 Lin M, Alnaggar M, Liang S, Wang X, Liang Y, Zhang M, et al. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Oncotarget. 2017;8(60):101795-807.","journal-title":"Oncotarget"},{"issue":"1","key":"key20260410133028_B18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","unstructured":"18 Lin M, Zhang X, Liang S, Luo H, Alnaggar M, Liu A, et al. Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5(1):215.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"key20260410133028_B19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis","volume":"32","author":"Shi","year":"2023","unstructured":"19 Shi J, Luo D, Wan X, Liu Y, Liu J, Bian Z, et al. Detecting the skewness of data from the five-number summary and its application in meta-analysis. Stat Methods Med Res. 2023;32(7):1338-60.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"key20260410133028_B20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","unstructured":"20 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.","journal-title":"BMC Med Res Methodol"},{"key":"key20260410133028_B21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","unstructured":"21 Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"key20260410133028_B22","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","unstructured":"22 Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"key20260410133028_B23","volume-title":"Preface, \"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023).\"","author":"Bossuyt","year":"2023","unstructured":"23 Bossuyt PM, Deeks JJ, Leeflang MM, Takwoingi Y, Flemyng E. Preface, \"Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023).\" The Cochrane Collaboration; 2023. [cited 2024 oct 8]. Available from https:\/\/training.cochrane.org\/handbook-diagnostic-test-accuracy\/current"},{"issue":"3","key":"key20260410133028_B24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model","volume":"30","author":"Viechtbauer","year":"2005","unstructured":"24 Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. J Educ Behav Stat. 2005;30(3):261-93.","journal-title":"J Educ Behav Stat"},{"issue":"3","key":"key20260410133028_B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","unstructured":"25 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.","journal-title":"Control Clin Trials"},{"issue":"1","key":"key20260410133028_B26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The Combination of Estimates from Different Experiments","volume":"10","author":"Cochran","year":"1954","unstructured":"26 Cochran WG. The Combination of Estimates from Different Experiments. Biometrics. 1954;10(1):101.","journal-title":"Biometrics"},{"issue":"11","key":"key20260410133028_B27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","unstructured":"27 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.","journal-title":"Stat Med"},{"issue":"3","key":"key20260410133028_B28","first-page":"1643","article-title":"Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer","volume":"25","author":"Pan","year":"2020","unstructured":"28 Pan Q, Hu C, Fan Y, Wang Y, Li R, Hu X. Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer. JBUON. 2020;25(3):1643-9.","journal-title":"JBUON"},{"key":"key20260410133028_B29","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.2147\/JIR.S331023","article-title":"Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer","volume":"14","author":"He","year":"2021","unstructured":"29 He C, Sun S, Zhang Y, Li S. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. J Inflamm Res. 2021;14:4795-807.","journal-title":"J Inflamm Res"},{"issue":"26","key":"key20260410133028_B30","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","unstructured":"30 Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-32.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20260410133028_B31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line Immunotherapy for Non-Small-Cell Lung Cancer","volume":"40","author":"Reck","year":"2022","unstructured":"31 Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):586-97.","journal-title":"J Clin Oncol"},{"issue":"11","key":"key20260410133028_B32","doi-asserted-by":"crossref","first-page":"1652532","DOI":"10.1080\/2162402X.2019.1652532","article-title":"Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation","volume":"8","author":"Scheffer","year":"2019","unstructured":"32 Scheffer HJ, Stam AG, Geboers B, Vroomen LG, Ruarus A, de Bruijn B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. OncoImmunology. 2019;8(11):1652532.","journal-title":"OncoImmunology"},{"issue":"2","key":"key20260410133028_B33","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.39","article-title":"T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer","volume":"10","author":"He","year":"2020","unstructured":"33 He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med. 2020;10(2):e39.","journal-title":"Clin Transl Med"},{"issue":"10","key":"key20260410133028_B34","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/2326-6066.CIR-19-0101","article-title":"Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model","volume":"7","author":"Narayanan","year":"2019","unstructured":"34 Narayanan JS, Ray P, Hayashi T, Whisenant TC, Vicente D, Carson DA, et al. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunol Res. 2019;7(10):1714-26.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"key20260410133028_B35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","unstructured":"35 Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10(1):899.","journal-title":"Nat Commun"},{"issue":"4","key":"key20260410133028_B36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00262-007-0391-3","article-title":"Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas","volume":"57","author":"Bouet-Toussaint","year":"2008","unstructured":"36 Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pinti\u00e8re C, Daniel P, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother. 2008;57(4):531-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"key20260410133028_B37","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {\u03b3}\u03b4} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","unstructured":"37 Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {\u03b3}\u03b4} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7.","journal-title":"Cancer Res"},{"issue":"23","key":"key20260410133028_B38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","unstructured":"38 Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009;8(23):2211-20.","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"key20260410133028_B39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cac2.12068","article-title":"A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors","volume":"40","author":"Wei","year":"2020","unstructured":"39 Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, et al. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond). 2020;40(8):345-54.","journal-title":"Cancer Commun (Lond)"},{"key":"key20260410133028_B40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","unstructured":"40 Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78-87.","journal-title":"Eur J Cancer"},{"issue":"4","key":"key20260410133028_B41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/annonc\/mdw006","article-title":"CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"27","author":"Chiorean","year":"2016","unstructured":"41 Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016;27(4):654-60.","journal-title":"Ann Oncol"},{"key":"key20260410133028_B42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-94-017-7215-0_15","article-title":"CA 19-9: Biochemical and Clinical Aspects","volume":"867","author":"Scar\u00e0","year":"2015","unstructured":"42 Scar\u00e0 S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:247-60.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"key20260410133028_B43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdp332","article-title":"Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report","volume":"21","author":"Duffy","year":"2010","unstructured":"43 Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441-7.","journal-title":"Ann Oncol"},{"issue":"4","key":"key20260410133028_B44","first-page":"900","article-title":"Lewis antigennegative pancreatic cancer: an aggressive subgroup","volume":"56","author":"Liu","year":"2020","unstructured":"44 Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan Z, et al. Lewis antigennegative pancreatic cancer: an aggressive subgroup. Int J Oncol. 2020;56(4):900-8.","journal-title":"Int J Oncol"},{"issue":"1","key":"key20260410133028_B45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1148\/radiol.2019191109","article-title":"Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study","volume":"294","author":"Ruarus","year":"2020","unstructured":"45 Ruarus AH, Vroomen LG, Geboers B, van Veldhuisen E, Puijk RS, Nieuwenhuizen S, et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology. 2020;294(1):212-20.","journal-title":"Radiology"},{"issue":"2","key":"key20260410133028_B46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/00365521.2019.1575465","article-title":"Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility","volume":"54","author":"Flak","year":"2019","unstructured":"46 Flak RV, Stender MT, Jensen TM, Andersen KL, Henriksen SD, Mortensen PB, et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility. Scand J Gastroenterol. 2019;54(2):252-8.","journal-title":"Scand J Gastroenterol"},{"issue":"22","key":"key20260410133028_B47","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2169\/internalmedicine.0861-18","article-title":"Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan","volume":"57","author":"Sugimoto","year":"2018","unstructured":"47 Sugimoto K, Moriyasu F, Tsuchiya T, Nagakawa Y, Hosokawa Y, Saito K, et al. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan. Intern Med. 2018;57(22):3225-31.","journal-title":"Intern Med"},{"issue":"6","key":"key20260410133028_B48","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","unstructured":"48 Padr\u00f3n LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167-77.","journal-title":"Nat Med"},{"issue":"8","key":"key20260410133028_B49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","unstructured":"49 Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 2022;23(8):1009-20.","journal-title":"Lancet Oncol"},{"issue":"5","key":"key20260410133028_B50","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","article-title":"Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma","volume":"27","author":"Zheng","year":"2021","unstructured":"50 Zheng L, Ding D, Edil BH, Judkins C, Durham JN, Thomas DL 2nd, et al. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021;27(5):1278-86.","journal-title":"Clin Cancer Res"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:30:39Z","timestamp":1775827839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/irreversible-electroporation-combined-with-immunotherapy-versus-irreversible-electroporation-alone-for-locally-advanced-pancreatic-cancer-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"alternative-id":["10.31744\/einstein_journal\/2026RW1656"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026rw1656","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eRW1656"}}